Physician profile
Arkady Pinkhas
NPI 1861587438
$11,031.49
in general payments reported to CMS, 2019-2025
36 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,942 · 2020: $1,644 · 2021: $2,150 · 2022: $1,398 · 2023: $956 · 2024: $1,321 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,897.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,504.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,114.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $757.16 | 2019-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $614.95 | 2019-2023 | |
| Horizon Therapeutics Plc | $548.21 | 2019-2022 | |
| Amgen INC. | $546.47 | 2019-2025 | Otezla, Repatha, Repatha |
| Ironwood Pharmaceuticals, INC | $505.80 | 2020-2025 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $495.44 | 2019-2025 | Jardiance, Synjardy |
| Nestle Healthcare Nutrition INC. | $493.82 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $427.72 | 2019-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $415.30 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $361.14 | 2019-2025 | |
| Allergan, INC. | $356.08 | 2019-2020 | |
| Ardelyx, INC. | $296.69 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $276.27 | 2019-2023 | Jardiance |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arkady Pinkhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.